Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the diagnostic potential of biomarkers for invasive pulmonary aspergillosis in exhaled breath condensate.
| Condition |
|---|
|
Invasive Pulmonary Aspergillosis |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
- The identification of biomarkers for invasive pulmonary aspergillosis (IPA) in exhaled breath condensate (EBC) [ Time Frame: 15 months ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
exhaled breath condensate
| Estimated Enrollment: | 20 |
| Study Start Date: | January 2011 |
| Estimated Study Completion Date: | August 2013 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Invasive pulmonary aspergillosis (IPA)
Patients with proven or probable invasive pulmonary aspergillosis (IPA) (EORTC/MSG criteria)
|
|
Controls
Patients without signs of infection.
|
Detailed Description:
Invasive pulmonary aspergillosis (IPA) is a life-threatening infection in immunocompromised patients. The poor prognosis of the disease is partly attributed to difficulties encountered with the diagnosis of this infection. Invasive sampling procedures are often precluded in these patients. In addition, conventional diagnostic techniques lack sensitivity. Recently there has been increasing interest in the investigation of the lungs by noninvasive means including measurement of biomarkers in exhaled breath (e.g. NO) and those found in the cooled and condensed exhalate,termed EBC. It has been demonstrated that a measurable fraction of the EBC in healthy subjects is derived from aerosolized airway lining fluid. The presence of biomarkers for IPA will be investigated in EBC of patients with IPA, compared to controls.
Eligibility| Ages Eligible for Study: | 16 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Hospitalized adult patients of the department of Hematology, University Hospital, Leuven, Belgium
Inclusion Criteria:
- hospitalisation in the hematology department
- age > 16 years
- informed consent
- proven or probable IPA (EORTC/ MSG criteria)
- galactomannan positivity in BAL or serum
Exclusion Criteria:
- age < 16 years
Contacts and Locations| Contact: Edith Vermeulen | +32 16 34 79 25 | edith.vermeulen@uzleuven.be |
| Belgium | |
| UZ Leuven | Recruiting |
| Leuven, Belgium, 3000 | |
| Principal Investigator: Katrien Lagrou | |
| Sub-Investigator: Edith Vermeulen | |
More Information
No publications provided
| Responsible Party: | Edith Vermeulen, PhD fellow, Universitaire Ziekenhuizen Leuven |
| ClinicalTrials.gov Identifier: | NCT01247142 History of Changes |
| Other Study ID Numbers: | S52756 |
| Study First Received: | November 23, 2010 |
| Last Updated: | June 4, 2012 |
| Health Authority: | Belgium: Ethics Committee |
Keywords provided by Universitaire Ziekenhuizen Leuven:
|
invasive pulmonary aspergillosis exhaled breath condensate |
Additional relevant MeSH terms:
|
Aspergillosis Invasive Pulmonary Aspergillosis Pulmonary Aspergillosis Mycoses |
Lung Diseases, Fungal Lung Diseases Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 16, 2013